Cover Image
市場調查報告書

抗體藥物複合體(ADC):技術及全球市場

Antibody Drug Conjugates: Technologies and Global Markets

出版商 BCC Research 商品編碼 296130
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
抗體藥物複合體(ADC):技術及全球市場 Antibody Drug Conjugates: Technologies and Global Markets
出版日期: 2017年06月30日 內容資訊: 英文 132 Pages
簡介

抗體藥物複合體(ADC)的全球市場,預計從2016年的13億美元以25.5%的年複合成長率(CAGR)擴大到2021年的42億美元為規模。

本報告提供抗體藥物複合體(ADC)的全球市場調查,抗體藥物複合體的技術概要,產業結構,各技術、用途、標的抗原、地區的市場趨勢,市場規模、成長率的變化與今後的預測,市場的推動要素以及課題,專利概要,競爭情形,主要企業簡介等系統性資訊。

第1章 簡介

第2章 調查的主旨

第3章 市場趨勢、技術背景

  • 定義
  • 抗體藥物複合體(ADC)的結構要素
  • 抗體藥物複合體(ADC)的結構
  • 歷史觀點
  • 抗體藥物複合體(ADC)的優點
  • 已認證抗體藥物複合體(ADC)
    • Mylotarg
    • Adcetris
    • Kadcyla
  • 抗體藥物複合體(ADC)技術
  • 主要的抗體藥物複合體(ADC)的標的
    • CD19
    • CD20
    • CD22
    • CD25
    • CD30
    • CD33
    • CD40
    • CD56
    • CD74
    • CD70a,CD79b
    • CD138
    • CEACAM
    • EGFR
    • EGP-1
    • GPNMB
    • HER2
    • LIV-1
    • Mesothelin
    • Nectin-4
    • SLITRK6
    • VEGF
  • 單株抗體的種類
  • 低分子藥物的種類
  • 連接試劑的種類
  • 藥物複合技術
    • 傳統的複合技術
    • 局部的複合技術

第4章 抗體藥物複合體(ADC)的全球市場:各技術

  • 抗體藥物複合體(ADC)的全球市場:各低分子藥
  • 抗體藥物複合體(ADC)的全球市場:各單株抗體
  • 抗體藥物複合體(ADC)的全球市場:各連接試劑

第5章 抗體藥物複合體(ADC)的全球市場:各用途

  • 抗體藥物複合體(ADC)的全球市場:各癌症治療
    • 市場佔有率
    • 乳癌
    • 惡性淋巴腫瘤
    • 其他癌症

第6章 產業結構

  • 市場領導者
  • 市場佔有率

第7章 抗體藥物複合體(ADC)的全球市場:各地區

  • 市場概要
  • 收益
  • 抗體藥物複合體(ADC)的全球市場:各標的抗原

第8章 專利概要、近幾年趨勢

  • 專利分析
  • 近幾年趨勢
  • 法規上的問題

第9章 市場機會分析

  • 市場的推動要素
  • 市場課題
  • 生產策略

第10章 企業簡介

附錄:簡稱一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM161B

The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021

Report Includes

  • An overview of the global market for antibody drug conjugates as a part of the pharmaceutical industry that is looking for innovative technologies.
  • Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Examination of key market drivers and challenges.
  • Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.

Report Scope

Antibody drug conjugates are mainly used to treat cancer and are safer and more effective than many other cancer therapies. This report focuses on the global market for antibody drug conjugate products and provides an updated review, including their basic design and application in various areas of the biomedical sciences. The report covers three main areas of application, breast cancer, lymphoma and other cancers, including acute myeloid leukemia. The scope of this study includes the current market for ADCs. The report also discusses regulatory aspects, current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations and opportunities and the latest trends in ADC market are also discussed in the report.

Also included in the report is an analysis of relevant patents and profiles of companies that lead the antibody drug conjugate product market. Seattle Genetics Inc., Takeda Pharmaceuticals Co. Ltd. and Genentech Inc. are the major players in the market for ADCs at present.

Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis, and sales are broken down geographically into North America, Europe, Asia-Pacific and the emerging markets. The application of ADCs in various types of cancer is discussed from both a commercial perspective and that of a research and development (R&D) perspective.

The report only covers antibody drug conjugates in which an antibody is conjugated with small-molecule cytotoxins (payload) through a linker. ADCs are a form of antibody conjugates. Other forms of antibody conjugates such as radioisotope conjugated with an antibody are beyond the scope of this report. The study also does not cover mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC.

Analyst Credentials

SHALINI DEWAN focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports.

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Definitions
  • Components of ADCs
  • How ADCs Work
  • Historical Perspective.
  • Advantages of ADCs
  • Approved ADCs
    • Mylotarg (Gemtuzumab Ozogamicin)
    • Adcetris (Brentuximab Vedotin)
    • Kadcyla (Trastuzumab-DM1)
  • Antibody Drug Conjugation Technologies
  • Key ADC Targets
    • CD19
    • CD20
    • CD22
    • CD25
    • CD30
    • CD33
    • CD40
    • CD56
    • CD74
    • CD79a and CD79b
    • CD138 (Syndecan-1)
    • CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)
    • EGFR (Epidermal Growth Factor Receptor/ERBB1)
    • EGP-1 (Epithelial Glycoprotein-1 Antigen)
    • GPNMB
    • HER2 (Human Epidermal Growth Factor Receptor)
    • LIV-1
    • Mesothelin
    • Nectin-4
    • Prostate-Specific Membrane Antigen (PSMA)
    • SLITRK6
    • VEGF (Vascular Endothelial Growth Factor)
  • Types of Monoclonal Antibodies
  • Types of Payloads (Cytotoxic Agents)
  • Types of Linkers.
  • Conjugation Methods
    • Conventional Conjugation Method
    • Site-Specific Conjugation

Chapter 4: Market Breakdown by Technology Type

  • Market for ADCs by Type of Payload
    • Market Overview
    • Market Revenues
  • Market for ADCs by Type of Monoclonal Antibody
    • Market Overview
    • Market Revenues
  • Market for ADCs by Type of Linker
    • Market Overview
    • Market Revenues

Chapter 5: Market Breakdown by Application

  • Global Market for the Application of ADCs in Treating Various Types of Cancers
    • Market Share
    • Breast Cancer
    • Lymphoma
    • Other Types of Cancer

Chapter 6: Industry Structure

  • Market Leaders
  • Market Share

Chapter 7: Market Breakdown by Region

  • Market Overview
  • Market Revenues
  • Market for ADCs by Target Antigen
    • Market for CD-30 Targeting ADCs
    • Market for HER2 Targeting ADCs
    • Market for Other Antigen Targeting ADCs

Chapter 8: Patent Review/New Developments

  • Patent Analysis
    • Patents by Year
    • Patents by Company
    • Patents by Country
    • Patents by Assignee
  • New Developments
    • CMC-544
    • CDX-011
    • RG7596 (Polatuzumab Vedotin)
    • RG7593 (Pinatuzumab Vedotin)
    • PSMA ADC
    • IMGN853 (Mirvetuximab Soravtansine)
    • BT-062
  • Regulatory Issues
    • Regulatory History of Approved ADCs
    • Regulatory Exclusivity
    • Other Regulatory Issues

Chapter 9: Analysis of Market Opportunities

  • Key Drivers
    • Patent Expiration
    • Targeted Nature of ADCs
    • Complexity of ADCs
    • Investor Confidence in Biologics
    • Increased Research on ADC Development
    • Other Factors
  • Key Challenges
  • Manufacturer Strategies

Chapter 10: Company Profiles

Appendix: Abbreviations

About BCC Research

  • About BCC Research.
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 1 History of Antibody Drug
  • Table 2 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody
  • Table 3 Significant Antibody Drug Conjugate Payloads
  • Table 4 Significant Antibody Drug Conjugate Linkers
  • Table 5 Commercially Available Antibody Drug Conjugates: Key Components and Target Antigens
  • Table 6 Antibody Drug Conjugates with Significant Market Potential During the Forecast Period
  • Table 7 Global Market for Antibody Drug Conjugates, by Type of Payload, Through 2021 ($ Millions)
  • Table 8 Global Market for Antibody Drug Conjugates, by Type of mAb, Through 2021 ($ Millions)
  • Table 9 Global Market for Antibody Drug Conjugates, by Type of Linker, Through 2021 ($ Millions)
  • Table 10 Global Market for Antibody Drug Conjugates, by Type of Cancer, Through 2021 ($ Millions)
  • Table 11 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
  • Table 12 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 13 Global Market for Lymphoma Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 14 Global Market for Other Types of Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 15 Leading Manufacturers/Suppliers of Antibody Drug Conjugates, 2016
  • Table 16 Global Market Shares of Manufacturers/Suppliers for Antibody Drug Conjugates, 2016 (%)
  • Table 17 Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 18 Significant Early Stage Clinical Trials on Adcetris, 2017
  • Table 19 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 20 Significant Early Stage Clinical Trials on Kadcyla, 2017
  • Table 21 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 22 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 23 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb.2017
  • Table 24 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb.2017
  • Table 25 Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb.2017
  • Table 26 U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb.2017 (No./%)
  • Table 27 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb.2017
  • Table 28 Number of Investigational New Drug Applications Filed, 2003-2016
  • Table 29 ADCs in Research Pipeline as of Feb.9992017
  • Table 30 Orphan Drug Designations Granted for Adcetris
  • Table 31 Major Alliances for ADC Development
  • Table 32 Abbreviations Used in Antibody Drug Conjugates

List of Figures

  • Summary Figure: Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 1 Global Market for Antibody Drug Conjugates, by Type of Payload, 2014-2021 ($ Millions)
  • Figure 2 Global Market for Antibody Drug Conjugates, by Type of mAb, 2014-2021 ($ Millions)
  • Figure 3 Global Market for Antibody Drug Conjugates, by Type of Linker, 2014-2021 ($ Millions)
  • Figure 4 Global Market for Antibody Drug Conjugates, by Type of Cancer, 2014-2021 ($ Millions)
  • Figure 5 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
  • Figure 6 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 7 Global Market for Lymphoma Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 8 Global Market for Other Types of Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 9 Global Market Shares of Manufacturers/Suppliers of Antibody Drug Conjugates, 2016 (%)
  • Figure 10 Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 11 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 12 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 13 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 14 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb.2017
  • Figure 15 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb.2017
  • Figure 16 Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb.2017
  • Figure 17 U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb.2017 (%)
  • Figure 18 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb.2017
Back to Top